AMGEN INC | 76,00 Euro | +0,80 +1,06 % | |
| WKN: 867900 ISIN: US0311621009 Ticker-Symbol: AMG | Frankfurt | 19.06.13 | 16:11 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ-100S&P 100 S&P 500 NASDAQ Biotech |
|
| |||||||||||||||||||||
| |||||||||||||||||||||||
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 15:19 | Amgen In Focus | 5 | Seeking Alpha | |
| 15:04 | Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations | 34 | PR Newswire | |
| LOS ANGELES, June 19, 2013 /PRNewswire/ -- Biotechnology industry pioneer Amgen (NASDAQ: AMGN), is teaming up with financial software provider BlackLine Systems and enterprise application software... Mehr lesen zu: Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations | ||||
| 18.06. | Amgen bewegt sich innerhalb ihres Aufwärtstrends | 6 | GodmodeTrader.de | |
| 18.06. | Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals | 53 | PR Newswire | |
| NEW YORK, June 18, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting Amgen Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG), Vertex Pharmaceuticals... Mehr lesen zu: Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals | ||||
| 18.06. | Wunschanalyse der Woche: Amgen | 24 | Euro am Sonntag | |
| 17.06. | Watch for Amgen to Potentially Pullback After Gaining 1.70% Yesterday | 2 | SmarTrend | |
| 17.06. | Amgen Xgeva Label Expanded | - | Zacks | |
| 17.06. | Bullish Moving Average Cross by Amgen | 2 | SmarTrend | |
| 17.06. | Amgen share buybacks, drugs may fuel more stock gains - Barron's | 9 | Reuters.com | |
| 14.06. | Will Generic Competitors Of Enbrel Affect Amgen's Stock Price? | 2 | Seeking Alpha | |
| 14.06. | Amgen's XGEVA receives FDA approval to treat giant cell tumor of bone | 5 | Pharma Bus Review | |
| 14.06. | FDA backs new for Amgen drug for rare bone tumors | 4 | Yahoo-USA | |
| 14.06. | Amgen's Oncology Drug Meets Primary Endpoint | 2 | Zacks | |
| 13.06. | Amgen's Xgeva Approved for Giant-Cell Tumor of the Bone | 1 | Euroinvestor | |
| 13.06. | FDA Okays Amgen's XGEVA To Treat Giant Cell Tumor Of Bone | 12 | AFX News | |
| THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) said Thursday that the U.S. Food
and Drug Administration has approved a new indication for XGEVA (denosumab) as
the first and only treatment of... Mehr lesen zu: FDA Okays Amgen's XGEVA To Treat Giant Cell Tumor Of Bone | ||||
| 13.06. | FDA Approves Amgen's (AMGN) XGEVA for GCTB | - | StreetInsider.com | |
| 13.06. | FDA Approves Amgen's XGEVA (denosumab) For The Treatment Of Giant Cell Tumor Of Bone | 8 | PR Newswire | |
| THOUSAND OAKS, Calif., June 13, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab) for the... Mehr lesen zu: FDA Approves Amgen's XGEVA (denosumab) For The Treatment Of Giant Cell Tumor Of Bone | ||||
| 13.06. | Amgen Is A Value And Dividend Growth Story | 5 | Seeking Alpha | |
| 13.06. | FDA Issues Approval for Xgeva, Marketed by Amgen | - | Benzinga.com | |
| 13.06. | Why The Amgen And Cytokinetics Agreement Is Good News | 7 | Seeking Alpha | |
Seite: 1 2 3 4 5 ... Weiter >>
470 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von